{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T07:57:48Z","timestamp":1790495868884,"version":"4.1.0"},"reference-count":170,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["EXPL\/MEC-MGI\/1644\/2021"],"award-info":[{"award-number":["EXPL\/MEC-MGI\/1644\/2021"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["2021.08126"],"award-info":[{"award-number":["2021.08126"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.autrev.2026.104112","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T23:32:19Z","timestamp":1780356739000},"page":"104112","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dysregulation of helper, regulatory, and follicular CD4+ T cells in primary antiphospholipid syndrome: Immunopathology and implications for targeted immunomodulatory therapy"],"prefix":"10.1016","volume":"25","author":[{"given":"Pedro","family":"Gaspar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filipa","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e1lter R.","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasco C.","family":"Rom\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o E.","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Graca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2026.104112_bb0005","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1136\/ard-2023-224609","article-title":"2023 ACR\/EULAR antiphospholipid syndrome classification criteria","volume":"82","author":"Barbhaiya","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104112_bb0010","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1590\/1806-9282.66.11.1595","article-title":"Non-criteria antiphospholipid antibodies: a narrative review","volume":"66","author":"Funke","year":"2020","journal-title":"Rev Assoc Med Bras"},{"key":"10.1016\/j.autrev.2026.104112_bb0015","article-title":"Non-criteria antiphospholipid antibodies in antiphospholipid syndrome: diagnostic value added","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104112_bb0020","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1636171","article-title":"Criteria and non-criteria anti-phospholipid antibodies in the different clinical forms of antiphospholipid syndrome","volume":"16","author":"Cabrera-Marante","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104112_bb0025","article-title":"Antiphospholipid syndrome","volume":"4","author":"Schreiber","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.autrev.2026.104112_bb0030","article-title":"Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management","volume":"380","author":"Knight","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.autrev.2026.104112_bb0035","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1177\/0961203309106832","article-title":"The euro-phospholipid project: epidemiology of the antiphospholipid syndrome in Europe","volume":"18","author":"Cervera","year":"2009","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2026.104112_bb0040","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1111\/j.1538-7836.2006.02193.x","article-title":"Vascular endothelial growth factor expression in monocytes from patients with primary antiphospholipid syndrome","volume":"4","author":"Cuadrado","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.autrev.2026.104112_bb0045","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1182\/blood.2019003863","article-title":"Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS","volume":"135","author":"Chaturvedi","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2026.104112_bb0050","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1002\/art.41460","article-title":"Anti-neutrophil extracellular trap antibodies and impaired neutrophil extracellular trap degradation in antiphospholipid syndrome","volume":"72","author":"Zuo","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2026.104112_bb0055","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1002\/art.42489","article-title":"Anti\u2013neutrophil extracellular trap antibodies in antiphospholipid antibody\u2013positive patients: results from the antiphospholipid syndrome alliance for clinical trials and international networking clinical database and repository","volume":"75","author":"Zuo","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2026.104112_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.tmrv.2025.150909","article-title":"Analytical review: neutrophil extracellular traps and antiphospholipid syndrome","volume":"40","author":"Butt","year":"2026","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.autrev.2026.104112_bb0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0048111","article-title":"Cytokines induced neutrophil extracellular traps formation: implication for the inflammatory disease condition","volume":"7","author":"Keshari","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.autrev.2026.104112_bb0070","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1002\/eji.202048878","article-title":"IL-17A expressed on neutrophil extracellular traps promotes mesenchymal stem cell differentiation toward bone-forming cells in ankylosing spondylitis","volume":"51","author":"Papagoras","year":"2021","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.autrev.2026.104112_bb0075","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cytogfr.2024.12.001","article-title":"Cytokine signalling in formation of neutrophil extracellular traps: implications for health and diseases","volume":"81","author":"Manoj","year":"2025","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.autrev.2026.104112_bb0080","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1136\/annrheumdis-2018-213181","article-title":"REDD1\/autophagy pathway promotes thromboinflammation and fibrosis in human systemic lupus erythematosus (SLE) through NETs decorated with tissue factor (TF) and interleukin-17A (IL-17A)","volume":"78","author":"Frangou","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104112_bb0085","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1002\/art.39247","article-title":"Release of neutrophil extracellular traps by neutrophils stimulated with antiphospholipid antibodies: a newly identified mechanism of thrombosis in the antiphospholipid syndrome","volume":"67","author":"Yalavarthi","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2026.104112_bb0090","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.neuropharm.2018.06.001","article-title":"Anti-\u03b22GPI\/\u03b22GPI induces neutrophil extracellular traps formation to promote thrombogenesis via the TLR4\/MyD88\/MAPKs axis activation","volume":"138","author":"Zha","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.autrev.2026.104112_bb0095","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1055\/s-0038-1655994","article-title":"Different anticoagulant and immunological properties of anti-prothrombin antibodies in patients with antiphospholipid antibodies","volume":"77","author":"Galli","year":"1997","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.autrev.2026.104112_bb0100","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1182\/blood-2009-12-260976","article-title":"\u03b22-glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome","volume":"116","author":"A\u011far","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2026.104112_bb0105","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1182\/blood-2005-05-1943","article-title":"Pathogenic anti-\u03b22-glycoprotein I antibodies recognize domain I of \u03b22-glycoprotein I only after a conformational change","volume":"107","author":"De Laat","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2026.104112_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2019.100610","article-title":"The role of beta-2-glycoprotein I in health and disease associating structure with function: more than just APS","volume":"39","author":"McDonnell","year":"2020","journal-title":"Blood Rev"},{"key":"10.1016\/j.autrev.2026.104112_bb0115","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.4049\/jimmunol.170.6.3408","article-title":"Prothrombin binds to the surface of apoptotic, but not viable, cells and serves as a target of lupus anticoagulant autoantibodies","volume":"170","author":"D\u2019Agnillo","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2026.104112_bb0120","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1042\/BST20211254","article-title":"Dynamics of phagocytosis mediated by phosphatidylserine","volume":"50","author":"Vorselen","year":"2022","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.autrev.2026.104112_bb0125","doi-asserted-by":"crossref","DOI":"10.1002\/acr2.70122","article-title":"IgG and IgM anti-phosphatidylserine\/prothrombin complex antibody detection may improve classification accuracy of systemic lupus erythematosus and antiphospholipid antibody syndrome","volume":"7","author":"Donath","year":"2025","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.autrev.2026.104112_bb0130","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41420-024-02036-w","article-title":"Ru(II)-based complexes containing 2-thiouracil derivatives suppress liver cancer stem cells by targeting NF-\u03baB and Akt\/mTOR signaling","volume":"10","author":"Bomfim","year":"2024","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.autrev.2026.104112_bb0135","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-21750-8","article-title":"Exogenous phosphatidylserine protects against mesenteric ischemia-reperfusion with associated Akt\/mTOR pathway upregulation","volume":"15","author":"Hamaneh","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.autrev.2026.104112_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108620","article-title":"Targeting phosphatidylserine enhances the anti-tumor response to tumor-directed radiation therapy in a preclinical model of melanoma","volume":"34","author":"Budhu","year":"2021","journal-title":"Cell Rep"},{"key":"10.1016\/j.autrev.2026.104112_bb0145","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.3389\/fimmu.2018.02469","article-title":"Regulation of the germinal center response","volume":"9","author":"Stebegg","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104112_bb0150","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1084\/jem.20102477","article-title":"A dynamic T cell\u2013limited checkpoint regulates affinity-dependent B cell entry into the germinal center","volume":"208","author":"Schwickert","year":"2011","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2026.104112_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2024.101936","article-title":"B cell activation and autoantibody production in autoimmune diseases","volume":"38","author":"Sun","year":"2024","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.autrev.2026.104112_bb0160","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1053\/sarh.2003.49994","article-title":"A systematic analysis of sequences of human antiphospholipid and anti\u2013\u03b22-glycoprotein I antibodies: the importance of somatic mutations and certain sequence motifs","volume":"32","author":"Giles","year":"2003","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2026.104112_bb0165","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1111\/jth.13379","article-title":"IgG\/IgM antiphospholipid antibodies present in the classification criteria for the antiphospholipid syndrome: a critical review of their association with thrombosis","volume":"14","author":"Kelchtermans","year":"2016","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.autrev.2026.104112_bb0170","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/jth.14633","article-title":"The (non-)sense of detecting anti-cardiolipin and anti-\u03b22glycoprotein I IgM antibodies in the antiphospholipid syndrome","volume":"18","author":"Chayoua","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.autrev.2026.104112_bb0175","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1136\/annrheumdis-2019-215213","article-title":"EULAR recommendations for the management of antiphospholipid syndrome in adults","volume":"78","author":"Tektonidou","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104112_bb0180","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1111\/jth.14192","article-title":"McMaster RARE-best practices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome","volume":"16","author":"Legault","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.autrev.2026.104112_bb0185","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1145145","article-title":"An update on the biologics for the treatment of antiphospholipid syndrome","volume":"14","author":"Yun","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104112_bb0190","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1177\/09612033221128742","article-title":"Immunosuppression use in primary antiphospholipid antibody-positive patients: descriptive analysis of the antiphospholipid syndrome alliance for clinical trials and international networking (APS ACTION) clinical database and repository (\u201cregistry\u201d)","volume":"31","author":"Erton","year":"2022","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2026.104112_bb0195","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/art.1780380118","article-title":"Transfer of experimental antiphospholipid syndrome by bone marrow cell transplantation. The importance of the T cell","volume":"38","author":"Blank","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2026.104112_bb0200","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1002\/art.1780370819","article-title":"Suppression of experimental antiphospholipid syndrome and systemic lupus erythematosus in mice by anti-CD4 monoclonal antibodies","volume":"37","author":"Tomer","year":"1994","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2026.104112_bb0205","doi-asserted-by":"crossref","first-page":"5303","DOI":"10.4049\/jimmunol.161.10.5303","article-title":"Oral tolerance to low dose beta 2-glycoprotein I: immunomodulation of experimental antiphospholipid syndrome","volume":"161","author":"Blank","year":"1998","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2026.104112_bb0210","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jaut.2019.02.002","article-title":"Oral administration of domain-I of beta-2glycoprotein-I induces immunological tolerance in experimental murine antiphospholipid syndrome","volume":"99","author":"Shemer","year":"2019","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2026.104112_bb0215","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jaut.2014.06.001","article-title":"Tolerogenic dendritic cells specific for \u03b22-glycoprotein-I domain-I, attenuate experimental antiphospholipid syndrome","volume":"54","author":"Zandman-Goddard","year":"2014","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2026.104112_bb0220","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1136\/annrheumdis-2011-200063","article-title":"Tolerogenic dendritic cells inhibit antiphospholipid syndrome derived effector\/memory CD4+ T cell response to \u03b22GPI","volume":"71","author":"Torres-Aguilar","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104112_bb0225","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1177\/096120339500400111","article-title":"Association between HLA class II antigens and primary antiphospholipid syndrome from the south of Spain","volume":"4","author":"Camps","year":"1995","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2026.104112_bb0230","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/1529-0131(200001)43:1<65::AID-ANR9>3.0.CO;2-I","article-title":"T cells that are autoreactive to beta2-glycoprotein I in patients with antiphospholipid syndrome and healthy individuals","volume":"43","author":"Hattori","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2026.104112_bb0235","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1182\/blood.V98.6.1889","article-title":"Autoreactive CD4(+) T-cell clones to beta2-glycoprotein I in patients with antiphospholipid syndrome: preferential recognition of the major phospholipid-binding site","volume":"98","author":"Arai","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2026.104112_bb0240","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.V99.7.2499","article-title":"Restricted T-cell receptor beta-chain usage by T cells autoreactive to beta(2)-glycoprotein I in patients with antiphospholipid syndrome","volume":"99","author":"Yoshida","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2026.104112_bb0245","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.thromres.2004.06.029","article-title":"\u03b22-glycoprotein I: antiphospholipid syndrome and T-cell reactivity","volume":"114","author":"Kuwana","year":"2004","journal-title":"Thromb Res"},{"key":"10.1016\/j.autrev.2026.104112_bb0250","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/j.1365-2249.1994.tb07015.x","article-title":"Selective increase of activation antigens HLA-DR and CD38 on CD4+ CD45RO+ T lymphocytes during HIV-1 infection","volume":"95","author":"Kestens","year":"1994","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2026.104112_bb0255","doi-asserted-by":"crossref","first-page":"523","DOI":"10.4049\/jimmunol.2100011","article-title":"HLA-DR marks recently divided antigen-specific effector CD4 T cells in active tuberculosis patients","volume":"207","author":"Tippalagama","year":"2021","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2026.104112_bb0260","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jaci.2023.07.008","article-title":"Frequency of HLA-DR+CD38hi T cells identifies and quantifies T-cell activation in hemophagocytic lymphohistiocytosis, hyperinflammation, and immune regulatory disorders","volume":"153","author":"Nguyen","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.autrev.2026.104112_bb0265","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.3899\/jrheum.081079","article-title":"Quantitative abnormalities of peripheral blood distinct T, B, and natural killer cell subsets and clinical findings in obstetric antiphospholipid syndrome","volume":"36","author":"Carbone","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2026.104112_bb0270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/868652","article-title":"CD8+DR+ T-cells and C3 complement serum concentration as potential biomarkers in thrombotic antiphospholipid syndrome","volume":"2014","author":"Sarmiento","year":"2014","journal-title":"Autoimmune Dis"},{"key":"10.1016\/j.autrev.2026.104112_bb0275","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1093\/rheumatology\/ken349","article-title":"Immunological features of primary anti-phospholipid syndrome in connection with endothelial dysfunction","volume":"47","author":"Soltesz","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2026.104112_bb0280","doi-asserted-by":"crossref","first-page":"5543","DOI":"10.1074\/jbc.M114.619817","article-title":"\u03b22-glycoprotein I-specific T cells are associated with epitope spread to lupus-related autoantibodies","volume":"290","author":"Salem","year":"2015","journal-title":"J Biol Chem"},{"key":"10.1016\/j.autrev.2026.104112_bb0285","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.3389\/fimmu.2018.02836","article-title":"\u03b22-glycoprotein I-reactive T cells in autoimmune disease","volume":"9","author":"Rauch","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104112_bb0290","doi-asserted-by":"crossref","first-page":"5400","DOI":"10.1182\/blood-2023-187962","article-title":"Cytokine profiling in antiphospholipid syndrome demonstrates persistent immune dysregulation and a procoagulant phenotype","volume":"142","author":"Hubben","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2026.104112_bb0295","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1080\/08916930902828254","article-title":"T cells demonstrate a Th1-biased response to native \u03b22-glycoprotein I in a murine model of anti-phospholipid antibody induction: brief research report","volume":"42","author":"Tolomeo","year":"2009","journal-title":"Autoimmunity"},{"key":"10.1016\/j.autrev.2026.104112_bb0300","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1182\/blood-2005-03-1201","article-title":"Oxidized beta2-glycoprotein I induces human dendritic cell maturation and promotes a T helper type 1 response","volume":"106","author":"Buttari","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2026.104112_bb0305","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.3892\/mmr.2012.1055","article-title":"Th1\/Th2\/Th17\/Treg expression in cultured PBMCs with antiphospholipid antibodies","volume":"6","author":"Xiao","year":"2012","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.autrev.2026.104112_bb0310","article-title":"Anti-domain 1 \u03b22 glycoprotein antibodies increase expression of tissue factor on monocytes and activate NK cells and CD8+ cells in vitro","volume":"11","author":"Manukyan","year":"2020","journal-title":"Autoimmun Highl [Internet]"},{"key":"10.1016\/j.autrev.2026.104112_bb0315","article-title":"Imbalance of Th17 cells, Treg cells and associated cytokines in patients with systemic lupus erythematosus: a meta-analysis","volume":"15","author":"Huang","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104112_bb0320","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1177\/0961203315618267","article-title":"Signs of impaired immunoregulation and enhanced effector T-cell responses in the primary antiphospholipid syndrome","volume":"25","author":"Jakiela","year":"2016","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2026.104112_bb0325","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1007\/s10875-012-9857-y","article-title":"Decreased levels of circulating CD4+CD25+Foxp3+ regulatory T cells in patients with primary antiphospholipid syndrome","volume":"33","author":"Dal Ben","year":"2013","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.autrev.2026.104112_bb0330","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.autrev.2017.02.004","article-title":"Antiphospholipid antibodies disappearance in primary antiphospholipid syndrome: thrombosis recurrence","volume":"16","author":"Medina","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2026.104112_bb0335","doi-asserted-by":"crossref","first-page":"391","DOI":"10.3389\/fimmu.2019.00391","article-title":"Altered Th17\/Treg ratio in peripheral blood of systemic lupus erythematosus but not primary antiphospholipid syndrome","volume":"10","author":"\u00c1lvarez-Rodr\u00edguez","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104112_bb0340","article-title":"Circulating plasmablasts contribute to antiphospholipid antibody production, associated with type I interferon upregulation","volume":"10","author":"Hisada","year":"2019"},{"key":"10.1016\/j.autrev.2026.104112_bb0345","article-title":"Preliminary study on the imbalance between Th17 and regulatory T cells in antiphospholipid syndrome","volume":"13","author":"Yan","year":"2022","journal-title":"Front Immunol [Internet]"},{"key":"10.1016\/j.autrev.2026.104112_bb0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2022.102978","article-title":"Whole blood transcriptome identifies interferon-regulated genes as key drivers in thrombotic primary antiphospholipid syndrome","volume":"134","author":"Verrou","year":"2023","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2026.104112_bb0355","article-title":"Defective germinal center selection results in persistence of self-reactive B cells from the primary to the secondary repertoire in primary antiphospholipid syndrome","volume":"15","author":"Dieudonn\u00e9","year":"2024","journal-title":"Nat Commun [Internet]"},{"key":"10.1016\/j.autrev.2026.104112_bb0360","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.autrev.2026.104112_bb0365","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/cei.13647","article-title":"Follicular helper and follicular regulatory T cell subset imbalance is associated with higher activated B cells and abnormal autoantibody production in primary anti-phospholipid syndrome patients","volume":"206","author":"Long","year":"2021","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2026.104112_bb0370","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.rbr.2013.09.001","article-title":"Patients with systemic lupus erythematosus and secondary antiphospholipid syndrome have decreased numbers of circulating CD4+CD25+Foxp3+ Treg and CD3\u2013 CD19+ B cells","volume":"54","author":"Ben","year":"2014","journal-title":"Rev Bras Reumatol (Engl Ed)"},{"key":"10.1016\/j.autrev.2026.104112_bb0375","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.4049\/jimmunol.1601045","article-title":"IL-10 receptor signaling is essential for TR1 cell function in vivo","volume":"198","author":"Brockmann","year":"2017","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2026.104112_bb0380","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1032575","article-title":"Type 1 regulatory T cell-mediated tolerance in health and disease","volume":"13","author":"Freeborn","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104112_bb0385","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41591-018-0254-9","article-title":"A CD4+ T cell population expanded in lupus blood provides B cell help through interleukin-10 and succinate","volume":"25","author":"Caielli","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.autrev.2026.104112_bb0390","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110565","article-title":"CD4+ T-cell-derived IL-10 promotes CNS inflammation in mice by sustaining effector T cell survival","volume":"38","author":"Yogev","year":"2022","journal-title":"Cell Rep"},{"key":"10.1016\/j.autrev.2026.104112_bb0395","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/184574","article-title":"T helper subsets, peripheral plasticity, and the acute phase protein, \u03b11-antitrypsin","volume":"2015","author":"Baranovski","year":"2015","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.autrev.2026.104112_bb0400","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1365-2249.2005.02990.x","article-title":"Altered naive CD4 and CD8 T cell homeostasis in patients with relapsing-remitting multiple sclerosis: thymic versus peripheral (non-thymic) mechanisms","volume":"143","author":"Duszczyszyn","year":"2005","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2026.104112_bb0405","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/nri3567","article-title":"Human memory T cells: generation, compartmentalization and homeostasis","volume":"14","author":"Farber","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2026.104112_bb0410","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3390\/vaccines13020205","article-title":"Memory cells in infection and autoimmunity: mechanisms, functions, and therapeutic implications","volume":"13","author":"Giri","year":"2025","journal-title":"Vaccines"},{"key":"10.1016\/j.autrev.2026.104112_bb0415","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.immuni.2019.04.011","article-title":"T follicular helper cell biology: a decade of discovery and diseases","volume":"50","author":"Crotty","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.autrev.2026.104112_bb0420","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.imlet.2022.02.008","article-title":"T follicular cells: the regulators of germinal center homeostasis","volume":"244","author":"Ribeiro","year":"2022","journal-title":"Immunol Lett"},{"key":"10.1016\/j.autrev.2026.104112_bb0425","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/nm.2426","article-title":"Follicular regulatory T cells expressing Foxp3 and Bcl-6 suppress germinal center reactions","volume":"17","author":"Chung","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.autrev.2026.104112_bb0430","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/nm.2425","article-title":"Foxp3+ follicular regulatory T cells control the germinal center response","volume":"17","author":"Linterman","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.autrev.2026.104112_bb0435","doi-asserted-by":"crossref","first-page":"4553","DOI":"10.4049\/jimmunol.1101328","article-title":"Regulation of the germinal center reaction by Foxp3 + follicular regulatory T cells","volume":"187","author":"Wollenberg","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2026.104112_bb0440","series-title":"T-follicular helper cells [internet]","first-page":"41","article-title":"Identification of human blood and tissue T follicular regulatory (Tfr) cells by flow cytometry","author":"Ribeiro","year":"2022"},{"key":"10.1016\/j.autrev.2026.104112_bb0445","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1084\/jem.20171976","article-title":"P2X7 receptor restrains pathogenic Tfh cell generation in systemic lupus erythematosus","volume":"216","author":"Faliti","year":"2019","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2026.104112_bb0450","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005191","article-title":"Induction of ICOS+CXCR3+CXCR5+ TH cells correlates with antibody responses to influenza vaccination","volume":"5","author":"Bentebibel","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.autrev.2026.104112_bb0455","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.vaccine.2016.11.059","article-title":"Greater activation of peripheral T follicular helper cells following high dose influenza vaccine in older adults forecasts seroconversion","volume":"35","author":"Pilkinton","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.autrev.2026.104112_bb0460","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1073\/pnas.1520112113","article-title":"CXCL13 is a plasma biomarker of germinal center activity","volume":"113","author":"Havenar-Daughton","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2026.104112_bb0465","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s10238-021-00720-0","article-title":"Imbalance of circulating CTLA4+ follicular helper and follicular regulatory T cells in obstetric antiphospholipid syndrome","volume":"22","author":"Zhang","year":"2022","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.autrev.2026.104112_bb0470","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.immuni.2014.12.005","article-title":"The coinhibitory receptor CTLA-4 controls B cell responses by modulating T follicular helper, T follicular regulatory, and T regulatory cells","volume":"41","author":"Sage","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.autrev.2026.104112_bb0475","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.bbrc.2018.09.182","article-title":"CTLA-4 regulates T follicular regulatory cell differentiation and participates in intestinal damage caused by spontaneous autoimmunity","volume":"505","author":"Chao","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.autrev.2026.104112_bb0480","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1073\/pnas.1414576112","article-title":"CTLA-4 controls follicular helper T-cell differentiation by regulating the strength of CD28 engagement","volume":"112","author":"Wang","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2026.104112_bb0485","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/ni.3054","article-title":"Pathophysiology of T follicular helper cells in humans and mice","volume":"16","author":"Ueno","year":"2015","journal-title":"Nat Immunol"},{"key":"10.1016\/j.autrev.2026.104112_bb0490","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/eji.201545760","article-title":"T follicular helper (Tfh) cells in lupus: activation and involvement in SLE pathogenesis","volume":"46","author":"Blanco","year":"2016","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.autrev.2026.104112_bb0495","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0075319","article-title":"Circulating TFH subset distribution is strongly affected in lupus patients with an active disease","volume":"8","author":"Le Coz","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.autrev.2026.104112_bb0500","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1079668","article-title":"The emerging role of Th1 cells in atherosclerosis and its implications for therapy","volume":"13","author":"Chen","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104112_bb0505","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/imm.12595","article-title":"The T helper type 17\/regulatory T cell paradigm in pregnancy","volume":"148","author":"Figueiredo","year":"2016","journal-title":"Immunology"},{"key":"10.1016\/j.autrev.2026.104112_bb0510","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.placenta.2023.08.065","article-title":"The role of Th17 and Treg cells in normal pregnancy and unexplained recurrent spontaneous abortion (URSA): new insights into immune mechanisms","volume":"142","author":"Tang","year":"2023","journal-title":"Placenta"},{"key":"10.1016\/j.autrev.2026.104112_bb0515","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1538-7836.2009.03674.x","article-title":"Clinical course of high-risk patients diagnosed with antiphospholipid syndrome","volume":"8","author":"Pengo","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.autrev.2026.104112_bb0520","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002881","article-title":"Identifying high-risk profile in primary antiphospholipid syndrome through cluster analysis: French multicentric cohort study","volume":"9","author":"Guedon","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.autrev.2026.104112_bb0525","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1080\/14767058.2020.1732343","article-title":"The role of lymphocytic cells in infertility and reproductive failures in women with antiphospholipid antibodies","volume":"35","author":"Krivonos","year":"2022","journal-title":"J Matern Fetal Neonatal Med"},{"key":"10.1016\/j.autrev.2026.104112_bb0530","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/cei\/uxac105","article-title":"IL-2-based approaches to Treg enhancement","volume":"211","author":"Harris","year":"2023","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2026.104112_bb0535","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/nm.4148","article-title":"Low-dose interleukin-2 treatment selectively modulates CD4+ T cell subsets in patients with systemic lupus erythematosus","volume":"22","author":"He","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.autrev.2026.104112_bb0540","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1136\/annrheumdis-2015-207776","article-title":"Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus","volume":"75","author":"Von Spee-Mayer","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104112_bb0545","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s13075-021-02535-6","article-title":"Therapeutic potential of targeting Tfr\/Tfh cell balance by low-dose-IL-2 in active SLE: a post hoc analysis from a double-blind RCT study","volume":"23","author":"Miao","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2026.104112_bb0550","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104539","article-title":"A systematic review of interleukin-2-based immunotherapies in clinical trials for cancer and autoimmune diseases","volume":"90","author":"Raeber","year":"2023","journal-title":"eBioMedicine"},{"key":"10.1016\/j.autrev.2026.104112_bb0555","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/S0140-6736(18)30485-9","article-title":"Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1\/2 trial","volume":"391","author":"Lai","year":"2018","journal-title":"The Lancet"},{"key":"10.1016\/j.autrev.2026.104112_bb0560","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1002\/art.34502","article-title":"N-acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial","volume":"64","author":"Lai","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2026.104112_bb0565","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nrrheum.2015.172","article-title":"Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases","volume":"12","author":"Perl","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2026.104112_bb0570","first-page":"58","article-title":"Sirolimus selectively increases circulating Treg cell numbers and restores the Th17\/Treg balance in rheumatoid arthritis patients with low disease activity or in DAS28 remission who previously received conventional disease-modifying anti-rheumatic drugs","volume":"38","author":"Niu","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2026.104112_bb0575","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1056\/NEJMoa1312890","article-title":"Inhibition of the mTORC pathway in the antiphospholipid syndrome","volume":"371","author":"Canaud","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2026.104112_bb0580","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1053\/j.ajkd.2019.08.032","article-title":"mTORC pathway activation and effect of sirolimus on native kidney antiphospholipid syndrome nephropathy: a case report","volume":"76","author":"Dufour","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.autrev.2026.104112_bb0585","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s11926-020-00935-2","article-title":"Management of non-criteria manifestations in antiphospholipid syndrome","volume":"22","author":"Xourgia","year":"2020","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.autrev.2026.104112_bb0590","article-title":"Sirolimus monotherapy for thrombocytopenia in primary antiphospholipid syndrome: a pilot study from a tertiary referral center","volume":"13","author":"Xie","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104112_bb0595","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3390\/ijms19020589","article-title":"Peripheral B-cell subset distribution in primary antiphospholipid syndrome","volume":"19","author":"\u00c1lvarez-Rodr\u00edguez","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.autrev.2026.104112_bb0600","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000693","article-title":"Increased B-cell activating factor (BAFF)\/B-lymphocyte stimulator (BLyS) in primary antiphospholipid syndrome is associated with higher adjusted global antiphospholipid syndrome scores","volume":"4","author":"Van Den Hoogen","year":"2018","journal-title":"RMD Open"},{"key":"10.1016\/j.autrev.2026.104112_bb0605","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1600-065X.2010.00944.x","article-title":"B-cell stage and context-dependent requirements for survival signals from BAFF and the B-cell receptor","volume":"237","author":"Mackay","year":"2010","journal-title":"Immunol Rev"},{"key":"10.1016\/j.autrev.2026.104112_bb0610","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.cytogfr.2013.12.011","article-title":"The function of BAFF on T helper cells in autoimmunity","volume":"25","author":"Chen","year":"2014","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.autrev.2026.104112_bb0615","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.108796","article-title":"BAFF promotes T cell activation through the BAFF-BAFF-R-PI3K-Akt signaling pathway","volume":"114","author":"Hu","year":"2019","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.autrev.2026.104112_bb0620","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.cyto.2018.11.008","article-title":"BAFF-R and TACI expression on CD3+ T cells: interplay among BAFF, APRIL and T helper cytokines profile in systemic lupus erythematosus","volume":"114","author":"Salazar-Camarena","year":"2019","journal-title":"Cytokine"},{"key":"10.1016\/j.autrev.2026.104112_bb0625","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1002\/art.23764","article-title":"Prevention of murine antiphospholipid syndrome by BAFF blockade","volume":"58","author":"Kahn","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2026.104112_bb0630","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1177\/0961203316682102","article-title":"Belimumab in primary antiphospholipid syndrome","volume":"26","author":"Yazici","year":"2017","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2026.104112_bb0635","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1136\/annrheumdis-2019-216367","article-title":"Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus","volume":"79","author":"Chatzidionysiou","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104112_bb0640","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.autrev.2018.11.002","article-title":"Belimumab reduces antiphospholipid antibodies in SLE patients independently of hydroxychloroquine treatment","volume":"18","author":"Emmi","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2026.104112_bb0645","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/annrheumdis-2018-213496","article-title":"Anticardiolipin and anti-beta 2 glycoprotein-I antibodies disappearance in patients with systemic lupus erythematosus and antiphospholipid syndrome while on belimumab","volume":"77","author":"Sciascia","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104112_bb0650","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1177\/0961203319860191","article-title":"Autoantibodies\u2019 titre modulation by anti-BlyS treatment in systemic lupus erythematosus","volume":"28","author":"Cavazzana","year":"2019","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2026.104112_bb0655","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/art.40360","article-title":"Efficacy and safety of Atacicept in patients with systemic lupus erythematosus: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled, parallel-arm, Phase IIb study","volume":"70","author":"Merrill","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2026.104112_bb0660","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.clim.2006.12.006","article-title":"Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis","volume":"123","author":"Sfikakis","year":"2007","journal-title":"Clin Immunol"},{"key":"10.1016\/j.autrev.2026.104112_bb0665","doi-asserted-by":"crossref","first-page":"633","DOI":"10.3899\/jrheum.100729","article-title":"Phenotypic changes of lymphocytes in patients with systemic lupus erythematosus who are in longterm remission after B cell depletion therapy with rituximab","volume":"38","author":"Iwata","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2026.104112_bb0670","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1093\/rheumatology\/key428","article-title":"Effect of rituximab treatment on T and B cell subsets in lymph node biopsies of patients with rheumatoid arthritis","volume":"58","author":"Ramwadhdoebe","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2026.104112_bb0675","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12882-024-03521-1","article-title":"Rituximab may affect T lymphocyte subsets balance in primary membranous nephropathy","volume":"25","author":"Zhang","year":"2024","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.autrev.2026.104112_bb0680","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1412668","article-title":"Long-term use of rituximab increases T cell count in MS patients","volume":"15","author":"Bj\u00f6rnsson","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104112_bb0685","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/art.37759","article-title":"A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome","volume":"65","author":"Erkan","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2026.104112_bb0690","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/BOR.0000000000000269","article-title":"Treatment of catastrophic antiphospholipid syndrome","volume":"28","author":"Kazzaz","year":"2016","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.autrev.2026.104112_bb0695","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1117699","article-title":"Biological therapy in systemic lupus erythematosus, antiphospholipid syndrome, and Sj\u00f6gren\u2019s syndrome: evidence- and practice-based guidance","volume":"14","author":"Marinho","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104112_bb0700","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.971366","article-title":"Low dose versus standard dose rituximab for the treatment of antiphospholipid syndrome: a pilot study from a tertiary medical center","volume":"13","author":"Gan","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104112_bb0705","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.medcli.2014.01.034","article-title":"Efficacy and safety of rituximab in the treatment of primary antiphospholipid syndrome: analysis of 24 cases from the bibliography review","volume":"144","author":"Pons","year":"2015","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.autrev.2026.104112_bb0710","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1084\/jem.20161955","article-title":"Co-stimulatory function in primary germinal center responses: CD40 and B7 are required on distinct antigen-presenting cells","volume":"214","author":"Watanabe","year":"2017","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2026.104112_bb0715","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0017739","article-title":"IL-21 and IL-6 are critical for different aspects of B cell immunity and redundantly induce optimal follicular helper CD4 T cell (Tfh) differentiation","volume":"6","author":"Eto","year":"2011","journal-title":"PloS One"},{"key":"10.1016\/j.autrev.2026.104112_bb0720","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14647","article-title":"IL-21 restricts T follicular regulatory T cell proliferation through Bcl-6 mediated inhibition of responsiveness to IL-2","volume":"8","author":"Jandl","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.autrev.2026.104112_bb0725","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtauto.2025.100288","article-title":"The role of soluble CD40L in autoimmune diseases","volume":"10","author":"Mabrouk","year":"2025","journal-title":"J Transl Autoimmun"},{"key":"10.1016\/j.autrev.2026.104112_bb0730","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2023.156437","article-title":"The role of interleukin-21 in autoimmune diseases: mechanisms, therapeutic implications, and future directions","volume":"173","author":"Shbeer","year":"2024","journal-title":"Cytokine"},{"issue":"suppl 9","key":"10.1016\/j.autrev.2026.104112_bb0735","article-title":"Chimeric autoantigen-T cell receptor (CATCR)-T cell therapies to selectively target autoreactive B cells [abstract]","volume":"74","author":"Mog","year":"2022","journal-title":"Arthritis Rheumatol [Internet]"},{"key":"10.1016\/j.autrev.2026.104112_bb0740","article-title":"Chimeric antigen receptor T-cell therapy\u2019s role in antiphospholipid syndrome: a case report","volume":"188","author":"Schmelz","year":"2020","journal-title":"Br J Haematol [Internet]"},{"key":"10.1016\/j.autrev.2026.104112_bb0745","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jtha.2024.09.024","article-title":"Disappearance of antiphospholipid antibodies after anti-CD19 chimeric antigen receptor T-cell therapy of B-cell lymphoma in a patient with systemic lupus erythematosus and antiphospholipid syndrome","volume":"23","author":"Friedberg","year":"2025","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.autrev.2026.104112_bb0750","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2026.101075","article-title":"CD19 CAR-T therapy induces remission in refractory autoimmune hemolytic anemia with ITP and antiphospholipid syndrome","author":"Korte","year":"2026","journal-title":"Med"},{"key":"10.1016\/j.autrev.2026.104112_bb0755","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.jcyt.2024.12.015","article-title":"CXCR5-targeted chimeric antigen receptor T regulatory cells for the selective inhibition of follicular helper T cell and B cell interaction","volume":"27","author":"Murai","year":"2025","journal-title":"Cytotherapy"},{"key":"10.1016\/j.autrev.2026.104112_bb0760","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2023-000976","article-title":"High-dimensional analysis of T-cell profiling variations following belimumab treatment in systemic lupus erythematosus","volume":"10","author":"Maeda","year":"2023","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.autrev.2026.104112_bb0765","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1182\/blood-2013-04-494096","article-title":"The effect of rituximab on vaccine responses in patients with immune thrombocytopenia","volume":"122","author":"Nazi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2026.104112_bb0770","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2022.102827","article-title":"High T-cell response rate after COVID-19 vaccination in belimumab and rituximab recipients","volume":"129","author":"Fabris","year":"2022","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2026.104112_bb0775","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1177\/0961203317703495","article-title":"A randomized, open-label study to investigate the effect of belimumab on pneumococcal vaccination in patients with active, autoantibody-positive systemic lupus erythematosus","volume":"26","author":"Chatham","year":"2017","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2026.104112_bb0780","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/0047-6374(94)90016-7","article-title":"Adjuvant effect of low-dose interleukin-2 on antibody response to influenza virus vaccination in healthy elderly subjects","volume":"77","author":"Provinciali","year":"1994","journal-title":"Mech Ageing Dev"},{"key":"10.1016\/j.autrev.2026.104112_bb0785","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/annrheumdis-2019-215396","article-title":"Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial","volume":"79","author":"He","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104112_bb0790","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1177\/09612033251322927","article-title":"Risk factors for bleeding in patients with thrombotic antiphospholipid syndrome during antithrombotic therapy","volume":"34","author":"Gaspar","year":"2025","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2026.104112_bb0795","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.bbmt.2005.04.006","article-title":"Sirolimus-related toxicity in stem cell transplantation","volume":"11","author":"Busca","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.autrev.2026.104112_bb0800","doi-asserted-by":"crossref","first-page":"227","DOI":"10.15171\/apb.2016.031","article-title":"Interactions between sirolimus and anti-inflammatory drugs: competitive binding for human serum albumin","volume":"6","author":"Khodaei","year":"2016","journal-title":"Adv Pharm Bull"},{"key":"10.1016\/j.autrev.2026.104112_bb0805","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.healun.2010.08.010","article-title":"Increased risk of venous thromboembolism with a sirolimus-based immunosuppression regimen in lung transplantation","volume":"30","author":"Ahya","year":"2011","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.autrev.2026.104112_bb0810","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/j.1399-0012.2012.01677.x","article-title":"Sirolimus use and incidence of venous thromboembolism in cardiac transplant recipients","volume":"26","author":"Thibodeau","year":"2012","journal-title":"Clin Transplant"},{"key":"10.1016\/j.autrev.2026.104112_bb0815","doi-asserted-by":"crossref","first-page":"4892","DOI":"10.1182\/blood-2019-126974","article-title":"The risk of thromboembolism associated with treatment of ITP with rituximab: adverse event reported in two randomized controlled trials","volume":"134","author":"Garabet","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2026.104112_bb0820","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2024.102327","article-title":"Bleeding events in thrombotic antiphospholipid syndrome: prevalence, severity, and associated damage accrual","volume":"8","author":"Gaspar","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.autrev.2026.104112_bb0825","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1159\/000438747","article-title":"Recognition and management of oral mucosal injury caused by mammalian target of rapamycin inhibitors: a case series","volume":"8","author":"Meiller","year":"2015","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.autrev.2026.104112_bb0830","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1001\/jamadermatol.2020.5180","article-title":"Mucocutaneous adverse events associated with oral sirolimus for the treatment of vascular anomalies","volume":"157","author":"Grenier","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.autrev.2026.104112_bb0835","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/COC.0000000000000553","article-title":"Clinical features of rituximab-associated gastrointestinal toxicities","volume":"42","author":"Mallepally","year":"2019","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.autrev.2026.104112_bb0840","article-title":"CAR T-cell therapy: adverse events and management","volume":"10","author":"Adkins, Rn, Msn, Anp-C S","year":"2019","journal-title":"JADPRO [Internet]"},{"key":"10.1016\/j.autrev.2026.104112_bb0845","article-title":"Infections after chimeric antigen receptor (CAR)-T-cell therapy for hematologic malignancies","volume":"25","author":"Kampouri","year":"2023","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.autrev.2026.104112_bb0850","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/s41409-022-01756-w","article-title":"Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy","volume":"57","author":"Wudhikarn","year":"2022","journal-title":"Bone Marrow Transplant"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997226001266?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997226001266?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T07:28:49Z","timestamp":1790494129000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997226001266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":170,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1568997226001266"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104112","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dysregulation of helper, regulatory, and follicular CD4+ T cells in primary antiphospholipid syndrome: Immunopathology and implications for targeted immunomodulatory therapy","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104112","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104112"}}